Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Smart pathology slide scanner for diagnosis and patient-specific treatment recommendation in oncology

Project description

Digital pathology slide scanner for cancer diagnosis

There is a growing need for tools that help doctors diagnose and evaluate the effectiveness of drug treatments for cancer patients. The EIC-funded CancerScan project aims to meet this need by developing a digital pathology slide scanner that can (semi)automatically create a patient-specific tumour digital twin and simulate drug treatments. This digital twin will integrate multi-omics profiling of patient biopsies with standard clinical data, embedded within the scanner hardware. The project will map tumour communication, create biomedical knowledge graphs from experimental data, identify properties of communication networks, develop a mathematical framework for modelling treatment effects, and design hardware for medical digital twins. The primary focus will be on pancreatic cancer and analysis of how tumour microenvironment composition affects drug efficacy.

Objective

Our long-term vision is to develop a smart digital pathology slide scanner that can (semi)automatically generate a patient-specific tumour digital twin and simulate various drug treatments on such twin. The digital twin will be generated by combining slide-level multi-omics profiling of patients’ biopsies with other standard clinical data and will be hardware-embedded within a slide scanner.
This foundational architecture involves five pillars: experimental mapping of tumor communication, reconstruction of Biomedical Knowledge Graphs (KG) based on experimental data, identification of structural and temporal properties of communication networks, development of a mathematical framework for modeling treatment effects on a tumor, and the design of a novel hardware acceleration architecture for a medical digital twin.
As a model system, we will use pancreatic cancer, combining in vitro experiments with clinical data. We will analyze how tumor microenvironment composition affects cellular crosstalk and drug efficacy by developing, growing, and treating a series of tumor organoids with different TME compositions, and performing a detailed molecular analysis of samples. Clinical validation will involve matching organoid and patient biopsy structures, ensuring relevance and applicability of our findings, thanks to the participation of a hospital as a third party.
This project is the initial step towards a platform assisting doctors in improving the diagnosis and assessment of drug treatment efficacy for individual cancer patients so that each patient gets the best possible drug, with the best possible treatment regimen.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-PATHFINDEROPEN-01

See all projects funded under this call

Coordinator

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Net EU contribution
€ 201 395,00
Address
CALLE SERRANO 117
28006 Madrid
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost
€ 201 395,00

Participants (7)